Genetics Division, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Cancer Cell. 2013 Sep 9;24(3):365-78. doi: 10.1016/j.ccr.2013.08.004.
RAS genes are commonly mutated in cancer; however, RAS mutations are rare in breast cancer, despite frequent hyperactivation of Ras and ERK. Here, we report that the RasGAP gene, RASAL2, functions as a tumor and metastasis suppressor. RASAL2 is mutated or suppressed in human breast cancer, and RASAL2 ablation promotes tumor growth, progression, and metastasis in mouse models. In human breast cancer, RASAL2 loss is associated with metastatic disease; low RASAL2 levels correlate with recurrence of luminal B tumors; and RASAL2 ablation promotes metastasis of luminal mouse tumors. Additional data reveal a broader role for RASAL2 inactivation in other tumor types. These studies highlight the expanding role of RasGAPs and reveal an alternative mechanism of activating Ras in cancer.
RAS 基因在癌症中通常发生突变;然而,RAS 突变在乳腺癌中很少见,尽管 Ras 和 ERK 经常过度激活。在这里,我们报告 RasGAP 基因 RASAL2 作为肿瘤和转移抑制因子发挥作用。RASAL2 在人乳腺癌中发生突变或受抑制,RASAL2 缺失促进小鼠模型中的肿瘤生长、进展和转移。在人乳腺癌中,RASAL2 缺失与转移疾病相关;低 RASAL2 水平与腔 B 型肿瘤的复发相关;RASAL2 缺失促进腔型小鼠肿瘤的转移。其他数据揭示了 RasGAP 失活在其他肿瘤类型中的更广泛作用。这些研究强调了 RasGAPs 的作用不断扩大,并揭示了癌症中激活 Ras 的另一种机制。